Menu
Search
|

Menu

Close
X

Ritter Pharmaceuticals Inc RTTR.OQ (NASDAQ Stock Exchange Capital Market)

2.16 USD
+0.06 (+2.86%)
As of Jul 20
chart
Previous Close 2.10
Open 2.00
Volume 12,596
3m Avg Volume 19,135
Today’s High 2.21
Today’s Low 2.00
52 Week High 6.48
52 Week Low 1.90
Shares Outstanding (mil) 5.02
Market Capitalization (mil) 10.54
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.407
FY17
-5.313
FY16
-20.001
FY15
-18.520
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
0.81
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-77.94
13.18
Return on Equity (TTM)
vs sector
-140.54
15.09

EXECUTIVE LEADERSHIP

Ira Ritter
Executive Chairman of the Board, Chief Strategic Officer, Since 2014
Salary: $308,332.00
Bonus: $97,571.00
Andrew Ritter
President, Chief Executive Officer, Founder, Director, Since 2018
Salary: $324,010.00
Bonus: $117,180.00
John Beck
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Michael Step
Director, Since 2018
Salary: $376,269.00
Bonus: --
Noah Doyle
Independent Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1880 Century Park E Ste 1000
LOS ANGELES   CA   90067-1623

Phone: +1310.2031000

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

SPONSORED STORIES